Voxelotor and albuminuria in adults with sickle cell anaemia

early The of is glomerular rate patients. In contrast, in a similar cohort of patients with SCA who were not treated with voxelotor, albuminuria increased in three out of five patients. Our findings support the concept that haemolytic anaemia is of clinical importance in sickle cell nephropathy; they also point to the need for future investigation of voxelotor, an FDA- approved oral therapy designed to reduce haemolytic anaemia, for the treatment of sickle cell nephropathy.